Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …

Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the
introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the …

Abstract Purpose This Phase I study determined the maximum-tolerated dose (MTD) of
afatinib (Afatinib is an investigational compound and its safety and efficacy have not yet …

Objectives Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung …

Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …